Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trial
Por:
Miro, JM, Torres, F, Manzardo, C, Bonfill, E, Curran, A, Domingo, P, Podzamczer, D, Paredes, R, Force, L, Falco, V, Gutierrez, M, Saumoy, M, Castelli, A, Inciarte, A, Rovira, C, Cruceta, A, Hurtado, C, Climent, N, Lozano, F and Plana, M
Publicada:
1 ene 2026
Ahead of Print:
1 dic 2025
Resumen:
Objectives: The aim of this trial was to compare the immune reconstitution, virologic response, and safety of dolutegravir (DTG) vs. darunavir (DRV) boosted-based antiretroviral (ART) regimens in very advanced HIV patients. Methods: Phase IV, randomized (1:1 ratio), open-label trial, including adult (>= 18 years) ART-na & iuml;ve HIV-1+ patients with CD4+ cell counts <100 cells/pL from nine hospitals in Spain. Participants were randomized to lamivudine (3TC)/abacavir (ABC)/DTG (DTG arm) and 3TC/ABC/DRV + ritonavir (DRV/r arm). Primary endpoint: change in the absolute CD4+ cell number at 48 weeks in the modified intention-to-treat population. Trial Registration: NCT02337322. Results: In total, 104 patients (86.5% male, median (interquartile range [IQR]) age 41.0 (31.5, 47.0) years) were recruited and randomized to DTG (n = 52) and DRV/r arms (n = 52). Baseline median (IQR) CD4+ cell counts were 39.5 (16.0, 72.9) and 29.0 (8.0, 60.0) cells/pL in the DTG and DRV/r arms. They significantly increased by median (IQR) 206.5 (154.4, 310.5) and 180.0 (89.4, 314.0) cells/pL, respectively (p 0.2549); 29 (55.8%) and 21 (42.9%) (p 0.2343) patients, respectively, reached >200 cells/pL. Of the patients, 41 (78.8%) and 31 (63.3%) (p 0.1229) in the DTG and DRV/r arms, respectively, achieved undetectable viral loads at 48 weeks; differences were significant at weeks 4 (p < 0.0001) and 12 (p 0.0009). Inflammation and bacterial translocation markers decreased more in the DTG arm, median (IQR)-8 (- 11,-4) vs.-5 (- 9,-3) pg/mL (p 0.0357) and-972 (- 1334,-508) vs.-544 (- 1128,-292) g/mL (p 0.0565), respectively, at 48 weeks. Discontinuation rates were higher in the DRV/r arm (3/52 (5.8%) vs. 9/51 (18.4%); p 0.0526). Conclusions: DTG/3TC/ABC is safe and efficacious in very advanced ART-na & iuml;ve HIV + patients, induced a faster virologic response, and was superior to the DRV/r regimen in reducing inflammation and bacterial translocation markers at 48 weeks. Miro JM, dlin Microbiol Infect 2026;32:169 (c) 2025 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Filiaciones:
Miro, JM:
Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain
Reial Acad Med Catalunya, Barcelona, Spain
Torres, F:
Univ Autonoma Barcelona, Med Sch, Biostat Unit, Barcelona, Spain
Hosp Clin IDIBAPS, Med Stat Core Facil, Barcelona, Spain
Manzardo, C:
Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain
Bonfill, E:
Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Clin Trials Unit, Barcelona, Spain
Curran, A:
Hosp Univ Vall dHebron, Vall dHebron Inst Recerca VHIR, Infect Dis Serv, Barcelona, Spain
Domingo, P:
Hosp Univ Santa Creu i St Pau, HIV Unit, Barcelona, Spain
Podzamczer, D:
Hosp Univ Bellvitge, Bellvitge Biomed Res Inst IDIBELL, Dept Infect Dis, HIV & Sexually Transmitted Dis STD Unit, LHospitalet de Llobregat, Barcelona, Spain
Fight AIDS Fdn, Badalona, Spain
:
Fight AIDS Fdn, Badalona, Spain
Hosp Univ Germans Trias i Pujol, Infect Dis Serv, Badalona, Spain
Force, L:
Hosp Univ Mataro, Internal Med Serv, Barcelona, Spain
Falco, V:
Hosp Univ Vall dHebron, Vall dHebron Inst Recerca VHIR, Infect Dis Serv, Barcelona, Spain
Gutierrez, M:
Hosp Univ Santa Creu i St Pau, HIV Unit, Barcelona, Spain
Saumoy, M:
Hosp Univ Bellvitge, Bellvitge Biomed Res Inst IDIBELL, Dept Infect Dis, HIV & Sexually Transmitted Dis STD Unit, LHospitalet de Llobregat, Barcelona, Spain
Castelli, A:
Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain
Inciarte, A:
Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain
Rovira, C:
Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain
Cruceta, A:
Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Clin Trials Unit, Barcelona, Spain
Hurtado, C:
Univ Barcelona, Hosp Clin Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi Sunyer FRCB IDIBAPS i, Infect Dis Serv, Barcelona, Spain
Climent, N:
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain
Univ Barcelona, Hosp Clin FRCB IDIBAPS, HIV AIDS Unit, Barcelona, Spain
Lozano, F:
Hosp Clin Barcelona, Serv Immunol, Ctr Diagnost Biomed, Barcelona, Spain
FRCB IDIBAPS, Immunoreceptors Innate & Adapt Immun, Barcelona, Spain
Univ Barcelona, Dept Biomed, Barcelona, Spain
Plana, M:
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecciosas CIB, Madrid, Spain
Univ Barcelona, Hosp Clin FRCB IDIBAPS, AIDS Res Grp, Barcelona, Spain
|